Income statement, balance sheet and cash flow statement for the last 10 fiscal years, taken from the XBRL data Anterix Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
FY2026
Revenue
4.79
6.36
6.5
1.56
0.92
1.08
1.92
4.19
6.03
6.5
Cost of revenue
7.05
7.9
4.65
2.83
1.61
0.01
0
Gross profit
-2.26
-1.54
-0.75
-1.27
-0.69
1.08
1.92
Research and development
2.32
2.35
2.29
2.95
4.34
3.59
4.44
5.7
5.74
4.7
Selling and marketing
5.65
6.97
3.67
4.06
2.94
4.46
5.73
5.69
6.11
6.9
General and administrative
22.6
20.9
19.6
25.5
39.3
39.5
45.2
44.4
42.7
36.1
Operating expenses
30.5
30.2
42
Operating income
-32.8
-31.7
-42.7
-37.5
-54.8
-36.8
-16.5
-10.1
-11.7
93.9
Interest expense
0.01
0
Interest income
0.13
0.74
1.46
1.81
0.12
0.06
1.14
2.37
2.16
1.63
Other non-operating income
-0.03
-0.08
-0.03
0.5
0.41
0.26
0.27
0.23
0.08
0.14
Pre-tax income
-32.7
-31.1
-41.3
-35.2
-54.3
-36.5
-15.1
-7.52
-9.48
95.7
Income tax
6.5
-6.5
0.69
2.4
0.12
0.98
1.26
1.61
1.89
5.07
Net income
-39.2
-24.6
-42
-37.6
-54.4
-37.5
-16.3
-9.13
-11.4
90.6
EBITDA
-30.6
-28.9
-39.9
-33.9
-51.3
-35.4
-15
-9.28
-11.2
94.4
EPS, basic
-2.72
-1.70
-2.88
-2.29
-3.13
-2.07
-0.87
-0.49
-0.61
4.85
EPS, diluted
-2.72
-1.70
-2.88
-2.29
-3.13
-2.07
-0.87
-0.49
-0.61
4.83
Shares, basic (weighted)
14.4
14.5
14.6
16.4
17.4
18.1
18.8
18.8
18.6
18.7
Shares, diluted (weighted)
14.4
14.5
14.6
16.4
17.4
18.1
18.8
18.8
18.6
18.8
Balance sheet
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
FY2026
Cash and equivalents
124
98.3
76.7
137
118
106
43.2
60.6
47.4
98.5
Receivables
0.64
0.94
0.44
0.06
0
0
Inventory
0.13
0.17
Other current assets
0.87
0.85
1.18
4.64
3.51
10.1
2.44
3.91
2.8
4.68
Total current assets
126
100
78.3
142
121
116
59.5
73
60.8
120
Property, plant and equipment
14.5
12.8
9.83
7
3.57
2.95
3.61
2.06
1.3
0.83
Lease right-of-use assets
6.5
5.1
4.05
3.37
4.43
4.83
4.07
Intangible assets
0.21
0.2
0.18
Other non-current assets
0.37
0.49
0.85
0.18
1.21
4.11
1.23
1.33
1.19
0.55
Total assets
245
220
197
267
253
278
279
325
333
465
Accounts payable
0.67
0.48
0.74
0.65
0.5
1.04
0.76
0.7
1.13
0.7
Accrued liabilities
0.22
0.59
0.83
1.33
0.95
0.74
1.27
1.75
1.58
9.02
Deferred revenue
0.79
0.81
0.79
0.73
0.74
1.48
2.77
6.47
6.1
14.5
Total current liabilities
4.72
5.23
8.84
8.82
8.62
9.64
31.9
18
27.2
36
Lease liabilities
7.05
5.6
4.18
2.92
3.45
3.75
3
Other non-current liabilities
1.34
2.33
3
0.64
0.88
0.54
0.51
0.53
0.13
0
Total liabilities
17.6
11.8
16
22.3
40.5
91.7
98.8
164
177
203
Paid-in capital
331
336
349
451
473
500
518
533
549
565
Retained earnings
-103
-127
-168
-206
-260
-314
-338
-372
-392
-302
Shareholders' equity
228
209
181
245
213
186
180
161
157
262
Total equity
228
209
181
245
213
186
180
161
157
262
Total liabilities and equity
245
220
197
267
253
278
279
325
333
465
Shares outstanding
14.4
14.5
14.7
17.2
17.7
18.4
18.9
18.5
18.6
18.9
Cash flow statement
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
FY2026
Net income
-39.2
-24.6
-42
-37.6
-54.4
-37.5
-16.3
-9.13
-11.4
90.6
Depreciation and amortization
2.23
2.85
2.85
3.59
3.53
1.45
1.42
0.84
0.55
0.46
Stock-based compensation
4.74
5.6
10.3
5.83
15.9
13.6
17.9
15.5
13.5
11.5
Deferred income tax
6.5
-6.5
0.69
2.4
0.12
0.98
1.22
0.84
0.33
-0.28
Change in receivables
-0.17
-0.32
0.27
0.46
0.06
0
0
Change in inventory
-0.04
-0.05
0.17
Change in payables
-0.25
0.76
0.91
0.58
2.65
0.27
0.1
1.94
0.55
-1.71
Cash from operations
-26.5
-22
-23.1
-27.8
-9.96
17.9
-27.3
42
-29.3
5.51
Capital expenditures
-1.64
-0.95
-0.72
-0.46
-0.23
-1.05
-2.13
-0.31
-0.09
-0.03
Cash from investing
-2.39
-2.88
-1.67
-7.56
-14.2
-27.4
-27.1
8.09
22.8
40.5
Stock issued
0.15
0.27
3.37
94.2
0
0
1.73
0.78
3.65
5.35
Share buybacks
0
0
-15
-8.22
-24.7
-8.4
-0.99
Cash from financing
-0.49
-0.9
3.16
96.1
4.22
-2.42
-8.06
-25.1
-6.59
3.59
Net change in cash
-29.4
-25.8
-21.6
60.7
-19.9
-11.9
-62.4
24.9
-13.1
49.6
Free cash flow
-28.1
-22.9
-23.8
-28.3
-10.2
16.9
-29.4
41.7
-29.4
5.48
Interest paid
0.01
0
0
0
0
0
0
Income taxes paid
0.04
0.02
0.03
0.04
0.06
0.01
0.01
0.07
1.73
5.81
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $81.42 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Operating margin
1,011.0%
Operating income / revenue.
EBITDA margin
1,018.0%
EBITDA (operating income + depreciation and amortization) / revenue.
Pre-tax margin
1,042.0%
Pre-tax income / revenue.
Net margin
933.0%
Net income / revenue.
FCF margin
151.0%
Free cash flow (cash from operations - capital expenditures) / revenue.
Operating cash flow margin
151.9%
Cash from operations / revenue.
Effective tax rate
10.5%
Income tax / pre-tax income, when pre-tax income is positive.
Return on equity (ROE)
23.0%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
13.2%
Net income / average total assets.
Return on invested capital (ROIC)
37.5%
Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
R&D / revenue
68.2%
Research and development expense / revenue.
Stock-based pay / revenue
158.2%
Stock-based compensation (from the cash flow statement) / revenue.
Capex / revenue
1.0%
Capital expenditures / revenue.
D&A / revenue
6.3%
Depreciation and amortization / revenue.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
7.8%
Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y
50.2%
Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Revenue CAGR, 5y
47.8%
Compound annual growth of revenue over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Book value growth, 1y
67.5%
Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y
13.4%
Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value CAGR, 5y
4.3%
Compound annual growth of book value over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y
39.7%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
18.6%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
13.0%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
1.0%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
-0.2%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
1.5%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
4.85x
Current assets / current liabilities.
Quick ratio
3.68x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
3.68x
(Cash + short-term investments) / current liabilities.
Free cash flow / net income, when net income is positive.
Capex / operating cash flow
0.6%
Capital expenditures / cash from operations, when that is positive.
Per share
Metric
Value
How it is calculated
EPS, diluted
$3.35
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share
$0.36
Revenue / diluted weighted shares.
FCF per share
$0.54
Free cash flow / diluted weighted shares.
Operating cash flow per share
$0.54
Cash from operations / diluted weighted shares.
Book value per share
$14.62
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/E
24.3x
Market cap / net income. Only when net income is positive.
P/S
227x
Market cap / revenue.
P/B
5.59x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
5.59x
Market cap / tangible book value, when positive.
P/FCF
150x
Market cap / free cash flow. Only when free cash flow is positive.
P/OCF
149x
Market cap / cash from operations, when positive.
EV/Sales
210x
Enterprise value / revenue.
EV/EBIT
20.8x
Enterprise value / operating income, when both are positive.
EV/EBITDA
20.7x
Enterprise value / EBITDA, when both are positive.
EV/FCF
139x
Enterprise value / free cash flow, when both are positive.
FCF yield
0.7%
Free cash flow / market cap.
Earnings yield
4.1%
Net income / market cap (the inverse of P/E).
What was Anterix Inc.'s revenue in fiscal 2026?
Anterix Inc. reported revenue of $6.5M for fiscal 2026, 7.8% higher than the year before.
Was Anterix Inc. profitable in fiscal 2026?
Yes. Net income was $90.6M, a net margin of 1,394.2%.
How much free cash flow did Anterix Inc. generate in fiscal 2026?
Cash from operations of $5.5M minus capital expenditures of $31.0K left free cash flow of $5.5M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.